ePT--the Electronic Newsletter of Pharmaceutical Technology, May 5, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
ePT--the Electronic Newsletter of Pharmaceutical Technology, May 5, 2011
News
FDA to Study Online Drug Marketing
By Angie Drakulich
FDA is collecting public comments on a series of studies that the agency plans to conduct on online direct-to-consumer promotion of prescription drug products, according to an announcement in the Federal Register.
Teva Snatches Cephalon from Valeant
By Rich Whitworth
Israel-based Teva Industries seals deal to acquire Cephalon for $6.8 billion.
PhRMA Urges Congress to Reauthorize Legislation for Pediatric Drugs
By Patricia Van Arnum
PhRMA Urges Congress to Reauthorize Legislation for Pediatric Drugs.
Excipient-Certification Standards Presented for Comment
By Erik Greb
The IPEC is soliciting public comment about a draft plan for the independent certification of manufacturers and suppliers of pharmaceutical excipients.
Federal Appeals Court Lifts Ban on Funding for Embryonic Stem Cell Research
By Amy Ritter
A federal appeals court has lifted a ban on federal funding for embryonic stem cell research.
Week of May 5, 2011: Company and People Notes: Velesco partners with Vindonwestech; NeurogesX announces retirement of CEO Anthony DiTonno; and More.
Velesco partners with Vindonwestech; NeurogesX announces retirement of CEO Anthony DiTonno; and More.
Regulatory Roundup: FDA Calling on Industry to Provide Feedback on Existing Regulations
FDA Calling on Industry to Provide Feedback on Existing Regulations.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
15%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here